• Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust

  • Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust
  1. Home
  2. Medicinal Marijuana

Medicinal Marijuana

Capture gf.JPG

No mention of cannabis legalisation at US Democrat National Convention

Finfeed Archived Aug 28, 2020

Despite the pro-cannabis atmosphere in 2019 during the Democrat primaries and Biden's and Harris's evolving stances on cannabis, there were no comments on cannabis legalization in the 2020 DNC.

Capture gf.JPG

Will 2021 be the year the cannabis industry makes a comeback?

Finfeed Archived May 08, 2020

The bubble has officially burst when it comes to the global cannabis market, yet it seems increasingly likely that 2021 will be a rebound year industry — once the coronavirus pandemic eases and markets begin to rally — but the path to profitability won't be easy.

MMJ logo new.png

MMJ’s Canadian cannabis investment Weed Me attracts new capital

Finfeed Archived Mar 10, 2020

Weed Me, one of the largest investments within MMJ Group’s cannabis and hemp portfolio, has completed a C$2.5 million capital raising.

Get expert stock analysis direct in your inbox

Join Our
Mailing List

Footer

Portfolio

  • Next Investors
  • Wise Owl
  • Catalyst Hunter
  • Next Biotech
  • Emerge

Support

  • Contact Us
  • Trust Centre
  • How it Works
  • History
  • FAQ
  • Definitions
  • Archived Articles
  • Bottom Drawer Portfolio

Policies

  • Customer Notice
  • Disclosure Policy
  • Financial Services Guide
  • ESG Policy
  • Privacy Policy

Subscribe Next Investors

Daily write ups on small cap stocks we are invested in:


Next Investors

This material has been prepared by S3 Consortium Pty Ltd (trading as StocksDigital). S3 Consortium Pty Ltd is a Corporate Authorised Representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.


© 2026 nextinvestors.com | All rights reserved

Follow Us